8149 The Effect of SGLT2 Inhibitors On NAFLD In Patients With Type 2 Diabetes: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials

荟萃分析 随机对照试验 2型糖尿病 医学 内科学 糖尿病 内分泌学
作者
Francinny Alves Kelly,Maria Eduarda Cavalcanti Souza,Artur Menegaz de Almeida,Ítalo Barros Andrade,Victória Morbach,Eric Pasqualotto,Matheus Budahazi Jardine,Renan Yuji Ura Sudo,Pedro Lucas Gomes Lima,Marianna G H S J Leite,Maria Luísa Siegloch Barros,Jorge Henrique Cavalcanti Orestes Cardoso,Izael Pereira da Silva,Francisco Cézar Aquino de Moraes,Felipe Dircêu Dantas Leite Pessôa,Artur de Oliveira Macena Lôbo,Lucca Moreira Lopes,Micael Porto Portela Lima
出处
期刊:Journal of the Endocrine Society [Endocrine Society]
卷期号:8 (Supplement_1)
标识
DOI:10.1210/jendso/bvae163.953
摘要

Abstract Disclosure: F.A. Kelly: None. M.C. Souza: None. A.M. De Almeida: None. I.B. Andrade: None. V. Morbach: None. E. Pasqualotto: None. M.B. Jardine: None. R.Y. Ura Sudo: None. P.G. Lima: None. M.G. Leite: None. M.S. Barros: None. J.C. Cardoso: None. I.P. da Silva: None. F.A. Moraes: None. F.D. Pessôa: None. A.D. Lôbo: None. L.M. Lopes: None. M.P. Lima: None. Type 2 diabetes (T2D) globally afflicts millions, entailing complications beyond hyperglycemia. Ectopic fat, the perilous accumulation of adipose tissue infiltrating vital organs, fuels a harmful cycle of insulin resistance and inflammation. Managing ectopic fat in T2D poses a significant challenge, compounded by non-alcoholic fatty liver disease (NAFLD) comorbidities that reduce life expectancy. Conventional interventions often inadequately address this issue. While current treatments predominantly target blood sugar, ectopic fat persists, contributing to complications like cardiovascular disease, fatty liver disease, and cancer. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), recognized for lowering blood sugar, have garnered interest for their potential impact on ectopic fat. These medications induce metabolic benefits beyond glycemic control by promoting urinary glucose excretion, presenting a promising avenue for addressing the intricate challenges of T2D.This meta-analysis aims to evaluate the potential of SGLT2 inhibitors, established glucose-lowering drugs in T2D, to reduce ectopic fat accumulation and mitigate its associated risks.PubMed, Embase, Web of Science, and Cochrane Library databases were systematically searched for randomized controlled trials (RCT) comparing the use of SGLT2i versus other therapies in patients with T2D and NAFLD. A random-effects model was used to calculate the mean differences (MD) with 95% confidence intervals (CI). Statistical analysis was performed in R software 4.3.1. A total of 9 RCTs comprising 558 patients were included, of whom 252 were randomized to SGLT2i therapy, 101 to pioglitazone, 166 to placebo, and 39 to other treatments. The mean follow-up was 21 weeks. In the pooled analysis, SGLT2i therapy was associated with a significant reduction in body weight (MD -1.81 kg; 95% CI -2.74,-0.88; p<0.001), alanine aminotransferase (ALT) (MD -4.29 U/L; 95% CI -8.35,-0.22; p=0.038), visceral adipose tissue (VAT) (MD -10.37 cm²; 95% CI -12.68,-8.06, p<0.001); and subcutaneous adipose tissue (SCAT) (MD -9.52 cm²; 95% CI -11.69, -7.34, p<0.001). There were no significant differences for body mass index (MD -0.14 kg/m2; 95% CI -0.94, 0.64; p=0.716), aspartate aminotransaminase (MD 1.18 U/L; 95% CI -3.96,6.34; p=0.651), controlled attenuation parameter (MD -2.44 dB/m; 95% CI -20.41,15.51; p=0.789), gamma-glutamyl transpeptidase (MD -1.10 U/L; 95% CI -15.73,13.52; p=0.882), and HbA1c (MD -0.13%; 95% CI -0.44,0.17; p=0.384).In this meta-analysis of RCTs of patients with T2D and NAFLD, the use of SGLT2i showed a significant reduction in body weight, ALT, SCAT, and VAT. Presentation: 6/3/2024

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
秋风的应助被耍酷的凝旋采纳,获得10
刚刚
刚刚
MST发布了新的文献求助10
刚刚
1秒前
myyang发布了新的文献求助10
1秒前
虚幻念寒完成签到 ,获得积分10
1秒前
1秒前
淡淡士晋发布了新的文献求助10
2秒前
2秒前
南淮完成签到,获得积分10
2秒前
Leo发布了新的文献求助10
2秒前
2秒前
2秒前
3秒前
leilei发布了新的文献求助10
3秒前
旗亭画壁完成签到 ,获得积分10
3秒前
fantasy的应助被天真的烨伟采纳,获得10
3秒前
4秒前
cxr完成签到,获得积分10
4秒前
机智的雀雀完成签到,获得积分10
4秒前
姚航完成签到,获得积分10
4秒前
5秒前
Jasper的应助被霁月采纳,获得10
5秒前
5秒前
研友_VZG7GZ的应助被醉卧星河采纳,获得10
5秒前
Ringo完成签到,获得积分10
5秒前
小巧妙梦发布了新的文献求助10
5秒前
庾傀斗发布了新的文献求助10
5秒前
5秒前
Ingram发布了新的文献求助10
6秒前
悦耳荧完成签到 ,获得积分10
6秒前
第一作者发布了新的文献求助10
7秒前
黄燕完成签到,获得积分10
7秒前
7秒前
7秒前
科研小冯发布了新的文献求助10
7秒前
九川完成签到,获得积分20
8秒前
方便面完成签到,获得积分10
8秒前
8秒前
我是谁的应助被gdd采纳,获得20
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187652
求助须知:如何正确求助?哪些是违规求助? 9575758
关于积分的说明 21842805
捐赠科研通 7785538
什么是DOI,文献DOI怎么找? 3435073
关于科研通互助平台的介绍 2559480
邀请新用户注册赠送积分活动 2481963